Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

The MHRA has advised that healthcare professionals remain vigilant for symptoms of acute pancreatitis, which may be ...

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: Medical weight loss is a personalized, medically ...

GLP1 and GIP receptor agonist – is now available in New Zealand.Mounjaro is a once weekly injectable medicine that acts on ...

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

People who don’t get the weight loss results they’re after on a GLP-1 medication like Wegovy (semaglutide) may switch to a dual-agonist drug like Zepbound (tirzepatide) under the guidance of their ...

If you live with obesity or type 2 diabetes, your doctor may have talked to you about GIP/GLP-1 agonist medications, such as tirzepatide (Mounjaro or Zepbound), which may help you lose weight. And ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...